Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1994-6-23
|
| pubmed:abstractText |
From 1978 to 1992, 276 patients (pts) with MGCT were treated in our institution. Forty-three of the pts were female (15.5%). Median age at diagnosis was 20 years (newborn-70). Histology was dysgerminoma (D) in 14 pts (including 2 anaplastic D), endodermal sinus tumor (EST) in 9 pts, immature teratoma in 10 pts and mixed tumors in 10 pts. Primary locations were as follows: ovary (O) 33 pts and extragonadal (EG) 10 pts (pineal in 4 cases, mediastinum in 3, sacrum in 2 and pharynx in 1). Stage: I in 20 (16 O, 4 EG), II in 7 (5 O, 2 EG), III in 12 (10 O, 2 EG) and IV in 4 (2 O, 2 EG). Serum AFP was elevated in 20/22 non-dysgerminoma pts, HCG in only 5 pts and LDH in 15/36 pts. TREATMENT RESULTS: Ovarian tumors: all but one pt (biopsy only) underwent surgery: unilateral oophorectomy was performed in 15 pts and bilateral oophorectomy (+/- hysterectomy, +/- others) in 17 pts. Fourteen pts were rendered disease-free, 8 pts had residual tumor (RT) < 2 cm and 11 RT > 2 cm. Chemotherapy (PVB or BEP) was given to 28 pts, radiotherapy to 2 pts and no additional treatment to 3. Finally, 30 pts achieved complete response (CR) and none have relapsed at a median follow-up of 43 months. EG tumors: None of the pts underwent radical surgery. Radiotherapy was applied to 4 pineal tumors and BEP or PVB were given to all 10 pts. To date 6 pts are disease-free, 1 is alive with mature teratoma, 2 are alive with disease and 1 died of toxic effects. The projected overall survival of the series as a whole is 89% at 10 years, and it is significantly higher for pts without EST (p < 0.02) and for pts with AFP < 1000 (P < 0.01) and age < 22 years at diagnosis (p < 0.01). The projected event-free survival at 10 years is 80.4% (87.7% for ovarian tumors vs. 54% for extragonadal, p = 0.05). No events were recorded after 28 months. CONCLUSIONS: The present results reflect the dramatic effectiveness of cisplatin-based chemotherapy for ovarian MGCT and confirm that unilateral oophorectomy can preserve fertility without compromising cure. Age > 22 years, histology (EST) and serum AFP > 1000 ng/ml are possible prognostic factors (univariate analysis) to be tested in an independent body of data on cisplatin-treated patients.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
0923-7534
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
5
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
225-31
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:7514435-Adolescent,
pubmed-meshheading:7514435-Adult,
pubmed-meshheading:7514435-Aged,
pubmed-meshheading:7514435-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:7514435-Bleomycin,
pubmed-meshheading:7514435-Child,
pubmed-meshheading:7514435-Cisplatin,
pubmed-meshheading:7514435-Etoposide,
pubmed-meshheading:7514435-Evaluation Studies as Topic,
pubmed-meshheading:7514435-Female,
pubmed-meshheading:7514435-Follow-Up Studies,
pubmed-meshheading:7514435-Germinoma,
pubmed-meshheading:7514435-Humans,
pubmed-meshheading:7514435-Middle Aged,
pubmed-meshheading:7514435-Neoplasm Staging,
pubmed-meshheading:7514435-Ovarian Neoplasms,
pubmed-meshheading:7514435-Ovariectomy,
pubmed-meshheading:7514435-Reoperation,
pubmed-meshheading:7514435-Survival Rate,
pubmed-meshheading:7514435-Treatment Outcome,
pubmed-meshheading:7514435-Vinblastine
|
| pubmed:year |
1994
|
| pubmed:articleTitle |
Ovarian and extragonadal malignant germ-cell tumors in females: a single-institution experience with 43 patients.
|
| pubmed:affiliation |
Division of Medical Oncology, 12 de Octubre University Hospital, Madrid, Spain.
|
| pubmed:publicationType |
Journal Article
|